<DOC>
	<DOCNO>NCT01857453</DOCNO>
	<brief_summary>Adult medulloblastoma rare tumour . The `` standard risk `` group ( complete surgery residual tumour lower 1,5 cm2 , absence malignant cell cerebrospinal fluid , absence metastasis , absence MYC amplification exclusion large cell medulloblastoma ) concern , adult population , majority patient diagnosis ( ¾ case ) . Conventional treatment classically base 54/36 Gy cranio-spinal radiotherapy ( 54 Gy posterior fossa 36 Gy nevraxis ) . This treatment associate acute toxicity ( haematological , cutaneous , digestive general ) wich decrease gradually patient go away treatment period . For category patient modality treatment , The French intergroup experience , plead favour late progressive neurotoxicity . This neurotoxicity associate clear degradation quality life . In light paediatric study : We propose phase II study estimate interest decrease radiation dos compensate chemotherapy accord follow schedule 1. carboplatine + etoposide base chemotherapy every 28 day x 2 2. follow , less 80 day surgery , radiation therapy 24 Gy toto neuro axis 54 Gy post operative bed . The majority French centre concern neuro-oncology involved trial . About 25 new case year wait . A centralized analysis pathological slide pre post surgery Magnetic Resonance Imaging foreseen . The main objective estimate survival without disease 1 year Secondary objective associate evaluation rate complete response end procedure , overall survival , survival without disease , survival without event , neurocognitiv toxicity , endocrine toxicity , hear toxicity time definitive deterioration quality life Associated study Two associated study besides foreseen ( parallel search co-financing ) : 1 . A biologic study plan aim confirm , morphological , genomic transcriptomic study , interest , adult population , prognostic marker use paediatric population 2 . A radiological study plan aim estimate interest : - multimodal follow-up ( spectroscopy perfusion image ) premature detection recurrences - study functional connectivity correlation neuropsychological follow-up analysis aetiology premature marker neurotoxicity .</brief_summary>
	<brief_title>Interest Dose Decrease Radiotherapy Associated With Chemotherapy Treatment Standard Risk Adult Medulloblastomas</brief_title>
	<detailed_description />
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<criteria>Pathologic diagnosis medulloblastoma expect large cell type Patients 18 70 year Résidual tumor les 1.5 square centimeter ( great diameter ) No sus tentorial spinal location Absence tumoral cell cerebrospinal fluid take , 14 day surgery Absence MYC amplification AID , B C hepatitis positive serology Negative βHCG dosage effective contraception potentially pregnant woman Writed consent obtain Age &lt; 18 &gt; 70 year Previous diagnosis medulloblastoma Previous treatment chemotherapy Previous cranial spinal radiation therapy Carboplatinum etoposide contraindication Previous cancer five year inclusion except basocellular carcinoma skin situ cancer uterine cervix Severe renal renal insufficiency creatinine clearance &lt; 60 ml/min Liver insufficiency contraindication carboplatinum etoposide base chemotherapy elevate transaminase &gt; 3N . Insufficient haematopoetic reserve ( thrombocytes &lt; 100 000/mm3 ou neutrophil polynuclear &lt; 1500/mm3 ) Previous organ transplantation immunosuppression Pregnant woman woman without contraception Incapacity respecting recommanded follow Participation another therapeutic clinical trial Patient custody Not social security regime membership</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Adult Patients Medulloblatoma Standard risk group Chemotherapy Radiotherapy Quality Life</keyword>
</DOC>